Parametric Portfolio Associates’s Spyre Therapeutics SYRE Stock Holding History

Parametric Portfolio Associates’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$409K	Buy	7,121 +5,442	+324%	+$457K	﹤0.01%	3179
2021 Q4	$199K	Sell	1,679 -125	-7%	-$19.7K	﹤0.01%	3429
2021 Q3	$359K	Buy	1,804 +478	+36%	+$83.6K	﹤0.01%	3230
2021 Q2	$231K	Buy	1,326 +262	+25%	+$47.6K	﹤0.01%	3355
2021 Q1	$211K	Buy	1,064 +6	+0.6%	+$1.15K	﹤0.01%	3860
2020 Q4	$208K	Buy	1,058 +48	+5%	+$9.95K	﹤0.01%	3757
2020 Q3	$179K	Sell	1,010 -195	-16%	-$36.1K	﹤0.01%	3691
2020 Q2	$279K	Buy	+1,205	New	+$229K	﹤0.01%	3504
2019 Q2	–	Sell	-450	Closed	-$91K	–	4000
2019 Q1	$91K	Buy	+450	New	+$93.8K	﹤0.01%	3828

Other funds holding SYRE

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Parametric Portfolio Associates's SYRE Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Spyre Therapeutics (SYRE) stake by 324% in Q1 2022, buying an estimated $457K and bringing the position to 7,121 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #3179.

Parametric Portfolio Associates first reported a position in SYRE in Q1 2019 and has held it in 9 quarters since. 83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

Parametric Portfolio Associates held 7,121 shares of Spyre Therapeutics worth $409K as of Q1 2022.
Parametric Portfolio Associates bought 5,442 Spyre Therapeutics shares in Q1 2022, an estimated $457K.
Spyre Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3179 holding.
Parametric Portfolio Associates first reported a position in Spyre Therapeutics in Q1 2019 and has held it in 9 quarters since.
83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.